首页> 外文会议>AIChE Annual Meeting >Challenges, Opportunities, and Scientific Aspects of Implementing PAT in Biopharmaceuticals
【24h】

Challenges, Opportunities, and Scientific Aspects of Implementing PAT in Biopharmaceuticals

机译:在生物制药中实施Pat的挑战,机会和科学方面

获取原文

摘要

As an essential milestone for both the cGMP for the 21~(St) Century and the recent pharmaceutical quality regulatory initiatives (Q8/Q9/Q10), the 2004 FDA Guidance for Industry "PAT-A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance" has proposed a science-based and risk-based regulatory pathway for pharmaceutical industry. Over the past 7 years the pace of implementation of PAT in small molecule drugs and biopharmaceuticals has been quite different. In this presentation, challenges and opportunities, technologies available as well as some scientific aspects of PAT real time process monitoring and control in biotech and biopharmaceutical area will be discussed based on several available case studies. In authors' opinion, when the pharmaceutical community is ready to embrace the challenges with enthusiasm, the benefits from implementing PAT in the biotech and biopharmaceutical area can be realized in the coming years.
机译:作为21〜(ST)世纪和最近的制药质量监管举措(Q8 / Q9 / Q10),2004年FDA工业指引的基本里程碑(Q8 / Q9 / Q10)“PAT-A框架创新的制药开发,制造业和质量保证“提出了一种基于科学和基于风险的制药行业的监管途径。在过去的7年里,小分子药物和生物制药的实施节奏已经完全不同。在这篇文章中,基于几种可用案例研究,将基于几种可用案例研究将讨论在生物技术和生物药物区域中提供的挑战和机遇,技术和帕特实时过程监测和控制的一些科学方面。在提交人的意见中,当制药界准备充满热情的挑战时,可以在未来几年实现实施PAT在生物技术和生物制药地区的福利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号